| Literature DB >> 22747904 |
Jürgen Kasper1, Sascha Köpke, Korbinian Fischer, Nina Schäffler, Imke Backhus, Alessandra Solari, Christoph Heesen.
Abstract
BACKGROUND: Patients making important medical decisions need to evaluate complex information in the light of their own beliefs, attitudes and priorities. The process can be considered in terms of the theory of planned behaviour. Decision support technologies aim at helping patients making informed treatment choices. Instruments assessing informed choices need to include risk knowledge, attitude (towards therapy) and actual uptake. However, mechanisms by which decision support achieves its goals are poorly understood.Our aim was therefore to develop and validate an instrument modeling the process of multiple sclerosis (MS) patients' decision making about whether to undergo disease modifying (immuno-)therapies (DMT).Entities:
Mesh:
Year: 2012 PMID: 22747904 PMCID: PMC3416666 DOI: 10.1186/1472-6947-12-60
Source DB: PubMed Journal: BMC Med Inform Decis Mak ISSN: 1472-6947 Impact factor: 2.796
Figure 1Illustration of theory of planned behaviour, I Ajzen [9].
Effects of educational intervention on PBMS parameters (validation trial)
| 1 Attitude | 3.5 (1.9) | 3.0 (1.8) | 0-9 | .04* | |
| | a: expectations regarding outcomes | 1.8 (0.6) | 1.6 (0.6) | 0-3 | .001* |
| | b: values of expected outcomes | 1.8 (0.6) | 1.8 (0.6) | 0-3 | .55 |
| 2 Social norm | 2.1 (1.2) | 1.7 (1.0) | 0-9 | .006* | |
| | a: assumed attitudes of important others | 1.9 (0.6) | 1.8 (0.7) | 0-3 | .28 |
| | b: motivation to comply with these norms | 1.1 (0.4) | 1.0 (0.4) | 0-3 | .004* |
| 3 Control beliefs | 3.2 (2.1) | 2.9 (2.1) | 0-9 | .313 | |
| | a: assumed facilitators or barriers | 1.6 (0.7) | 1.4 (0.8) | 0-3 | .14 |
| | b: perceived power of these factors | 1.8 (0.6) | 1.7 (0.7) | 0-3 | .42 |
| Intention estimate | 8.9 (4.1) | 7.5 (4.4) | 0-27 | .04* | |
P-values refer to unpaired t-tests comparing post intervention mean scores of intervention- and control groups. Theoretical range of scores is 0 to 3 for sub-domains, 0 to 9 for domains and 0 to 27 for intention estimate. “*” indicates statistically significant unpaired t-tests.
Predictive power of PBMS (Pre-test and RCT)
| | |||||
|---|---|---|---|---|---|
| | pre total n = 50 | r2 | .55(.54)* | .60(.57)* | .69(.65)* |
| pre sub s. n = 19 | r2 | .34(.31)* | .38(.30) | .56*(.42) | |
| | post sub s. n = 19 | r2 | .65(.63)* | .68(.61)* | .73(59)* |
| | pre total n = 177 | r2 | .41(41)* | .43(41)* | .50(48)* |
| post total n = 177 | r2 | .61(61)* | .63(62)* | .68(67)* | |
| | post CG n = 88 | r2 | .56(.56)* | .56(.55)* | .64(61)* |
| post IG n = 89 | r2 | .69(69)* | .74(73)* | .78(76)* | |
The table shows R-square(corrected R-square) values (indicating the percentage of explained variance) from predicting the criterion intention to use DMT (disease modifying therapy) using various predictor sets drawn from the PBMS in regression analyses.”*” = significance level <0.01. The pre-test sub sample (n = 19) includes participants of the PEPADIP pilot course who completed the PBMS twice (pre & post). RCT=randomized controlled trial.
Exploration of discriminatory validity using DMT status (pre-test) (N = 50)
| | ||||||
|---|---|---|---|---|---|---|
| 1: Attitude | 2.1 / 4.6 | 2.4 / 4.1 | 0-9 | <.01 | <.01 | |
| | a: expectations regarding outcomes | 1.4 / 2.0 | 1.5 / 1.9 | 0-3 | <.01 | <.01 |
| | b: values of expected outcomes | 1.4 / 2.2 | 1.5 / 2.1 | 0-3 | <.01 | <.01 |
| 2: Social norm | 1.2 / 1.8 | 1.5 / 2.4 | 0-9 | .23 | <.01 | |
| | a: assumed attitudes of important others | 1.2 / 2.0 | 1.5 / 2.2 | 0-3 | <.01 | <.01 |
| | b: motivation to comply with these norms | 1.0 / .9 | 1.0 / 1.1 | 0-3 | <.01 | .34 |
| 3: Control beliefs | 1.6 / 4.7 | 2.1 / 4.1 | 0-9 | <.01 | <.01 | |
| | a: assumed facilitators or barriers | 1.0 / 2.1 | 1.2 / 1.9 | 0-3 | <.01 | <.01 |
| | b: perceived power of these factors | 1.4 / 2.2 | 1.5 / 2.0 | 0-3 | <.01 | <.01 |
| Intention estimate | 4.8 / 11.1 | 6.0 / 10.1 | 0-27 | <.01 | <.01 | |
PBMS results are provided as means separately for groups using or not using DMT (disease modifying treatment), pre-test participants of (N = 50) and participants included in the randomized controlled trial (RCTN = 177). P values refer to unpaired t-tests comparing the two groups.
Demographic data
| Female (%) | 35 (70) | 74 (75) | 70 (75) | 144 (75) | .93 |
| Age (SD) | 41 (9) | 37 (10) | 36 (11) | 36 (11) | .61 |
| Years since diagnosis (SD) | 5 (6) | 2 (1) | 2 (1) | 2 (1) | .16 |
| Ongoing DMT (%) | 32 (64) | 55 (56) | 51 (55) | 106 (56) | .98 |
Values are frequencies (percentages) and means (SD). *P values refer to either chi-square tests or to unpaired t-tests. DMT = disease modifying treatment, RCT = randomized controlled trial.
Relative influence of PBMS domains
| 49 | 45 | .76 | |
| 31 | 21 | .51 | |
| 63 | 50 | .25 | |
The table illustrates the predictive power of single domains separately for the study groups. P values for differences between the percentages of explained variance as drawn from regression analyses were calculated using Fishers Z-test.